Patient-Centric
Optimized patient treatment planning and delivery at the core of everything we build.
Advancing how cancer is diagnosed & treated
NuView is a clinical-stage theranostics company on a mission to bring precision medicine to oncology — pairing diagnosis and therapy in a single targeted approach designed to be gentler on patients, with fewer off-target side effects than conventional treatment. We are actively seeking partners to help bring this approach to the patients who need it most.
Our Mission
Precision medicine for better outcomes
Our mission is to change the way many types of cancer are diagnosed and treated using precision medicine technology.
Diagnosing and treating cancer with a targeted, specific approach to the disease helps increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.
The versatility of the NV-VPAC1 technology platform enables us to pursue a program focused on developing new oncology products and new intellectual property for a range of cancer indications. NuView holds a robust IP position with a broad patent portfolio covering its platform, pipeline, and in vitro and in vivo products.
No Direct Competitors
A proprietary small molecule specifically targeting VPAC1 receptors.
University Origins
Built on technology developed at Thomas Jefferson University.
Management Team
Our leadership
Together, they are furthering NuView Life Sciences' mission to transform cancer diagnosis and treatment.
Paul J. Crowe
Chairman & CEO
Jill Helmke, PharmD, N.Ph
EVP of Clinical Development
Thomas G. Brown
Chief Financial Officer
Mathew Thakur, PhD
Clinical Collaborator
Steven J. Davis, Esq.
Outside Legal Counsel
Board of Directors
Industry leaders guiding our direction
Our team of industry leaders is trusted to guide the direction and decisions that will help NuView Life Sciences achieve its potential.
Paul J. Crowe
Chairman
Brian Cohen
Board Member
A.J. Boechler
Board MemberWant to learn more about our work?
Explore our technology pipeline or reach out to start a conversation.
Contact Us